- Title
- Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
- Creators
- John SARANTOPOULOS - Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA, University of Texas Health Science Center San Antonio, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, United StatesAlain C MITA - Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA, University of Texas Health Science Center San Antonio, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, United StatesJames L WADE - Cancer Care Center of Decatur, Decatur, IL, United StatesJohn C MORRIS - Division of Hematology-Oncology, Department of Medicine, University of Cincinnati Cancer Institute, Cincinnati, OH, United StatesOlivier RIXE - Division of Hematology/Oncology, GRU Cancer Center, Georgia Regents University, Augusta, GA, United StatesMonica M MITA - Institute for Drug Development, Cancer Therapy and Research Center at UTHSCSA, University of Texas Health Science Center San Antonio, 4th Floor, Zeller Building, 7979 Wurzbach Road, San Antonio, TX 78229, United StatesJean-François DEDIEU - Sanofi, Chilly-Mazarin, FranceClaudine WACK - Sanofi, Chilly-Mazarin, FranceLaurent KASSALOW - Sanofi, Bridgewater, NJ, United StatesA CRAIG LOCKHART - Siteman Cancer Center, Washington University School of Medicine, St. Louis, MO, United States
- Publication Details
- Cancer chemotherapy and pharmacology, Vol.74(6), pp.1113-1124
- Publisher
- Springer
- Language
- English
- Resource Type
- Journal article
- PMID
- 25307552
- Record Identifier
- 991031600918202976
Journal article
Phase I study of cabazitaxel plus cisplatin in patients with advanced solid tumors: study to evaluate the impact of cytochrome P450 3A inhibitors (aprepitant, ketoconazole) or inducers (rifampin) on the pharmacokinetics of cabazitaxel
Cancer chemotherapy and pharmacology, Vol.74(6), pp.1113-1124
2014
PMID: 25307552
Metrics
7 Record Views
InCites Highlights
These are selected metrics from InCites Benchmarking & Analytics tool, related to this output
- Collaboration types
- Industry collaboration
- Domestic collaboration
- International collaboration
- Citation topics
- 1 Clinical & Life Sciences
- 1.147 Prostate Cancer
- 1.147.859 Androgen Receptor
- Web Of Science research areas
- Oncology
- Pharmacology & Pharmacy
- ESI research areas
- Clinical Medicine
UN Sustainable Development Goals (SDGs)
This output has contributed to the advancement of the following goals:
Source: InCites